Great news but frustrating trading today. I'm putting the current SP situation all on the lack of certainty regarding Daybue sales growth this year. All we've heard to date is that there was a rebound in February from a low January. I just want to see that the current annual guidance is looking solid based on Q1 and projected Q2 then things can get back to the more important P2 trial results. Until those numbers are supported I don't expect to see any significant buy interest to counter the downward pressure. Last year the Q1 announcement was I think May 8 so likely not far away.
Ann: Trofinetide accepted for Priority Review by Health Canada, page-6
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.72 |
Change
-0.240(1.15%) |
Mkt cap ! $2.645B | |||
| Open | High | Low | Value | Volume |
| $21.00 | $21.21 | $20.31 | $15.80M | 766.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $20.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.72 | 3108 | 1 |
View Market Depth
| Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.75 |
Change
-0.240 ( 1.47 %) |
||||
| Open | High | Low | Volume | ||
| $20.97 | $21.15 | $20.32 | 199599 | ||
| Last updated 15.59pm 30/05/2024 ? | |||||
| NEU (ASX) Chart |